ArticleAnnals of medicine2025
Global, regional and national epidemiology of acute myeloid leukemia (1990-2021): a statistical analysis of incidence, mortality, and DALYs.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin.Journal of clinical medicine · 2026Review
- Global burden and trends of non-communicable diseases among children and adolescents from 1990 to 2021: an age-period-cohort and frontier analysis with projections to 2035.Frontiers in public health · 2026Article
- The transformative potential of lipid nanoparticles tailored for acute myeloid leukemia immunotherapy.Frontiers in immunology · 2026Review
- Deciphering Multitarget Mechanisms of Cardiac Glycosides in Acute Myeloid Leukemia Using a Network Pharmacology and Molecular Docking.Drug design, development and therapy · 2026Article
- Burden of dementia attributable to smoking among adults aged ≥40 years: A secondary dataset analysis of Global Burden of Disease 1990-2021 with projections to 2035.Tobacco induced diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study provides a comprehensive analysis of the global, regional, and national epidemiology of acute myeloid leukemia (AML) from 1990 to 2021, focusing on incidence, mortality, and disability-adjusted life years (DALYs).
methodsUsing data from the Global Burden of Disease (GBD) study, we investigated the trends and patterns of AML across 204 countries and territories during 1990 to 2021. All statistical analyses and data visualizations were performed using R (version 4.4.2) and JD_GBDR (V2.36).
resultsThe global incidence of AML increased by 82.25% from 79.37 × 10³ cases in 1990 to 144.65 × 10³ cases in 2021, with significant variations across regions. AML-related deaths increased by 73.77% globally, from 74.92 × 10³ in 1990 to 130.19 × 10³ in 2021. DALYs rose by 23.70%, from 3342.91 × 10³ in 1990 to 4135.06 × 10³ in 2021.
conclusionsHigh SDI regions face higher incidence and mortality due to advanced diagnostics and aging, while low-middle SDI regions show rapid increases likely due to urbanization and lifestyle changes. Addressing these disparities requires improved healthcare infrastructure, early detection, and targeted interventions, particularly in low- and middle-income countries (LMICs).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.